Yves Meyvis has been working in the biotech industry for twenty years. He holds a Master’s degree in Bio-engineering from KU Leuven, specializing in cell and gene technologies. In 2003, Yves gained his first international research experience at the University of Florida, working on novel vector expression systems to control malaria. In 2008, he obtained his Ph.D. in vaccine development at Ghent University, where he focused on identifying and recombinantly expressing potential immune targets to combat parasitic infections, including the purification and analytical characterization of newly discovered compounds. From 2009 to 2014, Yves worked as a Scientist and Team leader at Ablynx (now Sanofi) where he was responsible for the development of new Nanobody/VHH-based therapeutic products as part of the company’s CMC-team. From 2014 to 2016, he expanded his medical experience in the blood and cell therapy field working at Terumo BCT in a global science and technology function. Since 2016, he has been supporting the sales and marketing activities at RIC group. He is currently heading the Commercial department of RIC’s R&D laboratory, covering the roll-out of new life science applications and services throughout various sectors, including novel food.
Panel Discussion: Sourcing the right ingredients and processing technologies to usher in Plant Based 2.0
Convincing consumers that plant-based alternatives are not only sustainable for the environment but also tasty enough to repeatedly buy is proving to be a tricky proposition for manufacturers...
Europe's Meeting Place For Alternative Protein Production Solutions